ABSTRACT
OBJECTIVES: To investigate the epidemiological and clinicopathological features of breast cancer (BC) in Saudi Arabia to improve decisions regarding resource allocation, disease control, and management. METHODS: We retrieved the records of all patients who presented with histologically proven BC at King Fahad Medical City between 2019 and 2020. The data were analyzed quantitatively, and the results were expressed as percentages and frequencies. RESULTS: This study comprised 419 patients. The mean age was 50.13 (± 10.96) years. The majority of the patients were obese (56.6%), and approximately a quarter had a history of oral contraceptive pill use, breast biopsy, or an affected family member. Most cases were from the central region (80.1%), followed by the southern provinces (12.7%). Breast lumps were the most common complaint (89%), whereas hypertension and diabetes mellitus were the most common comorbidities. Invasive ductal carcinoma was the most common pathologic type (89.7%). Most patients presented with TNM stages II and III (55.2%), and 27.7% had metastasis. The main therapeutic modalities included radical mastectomy (63.8%), neoadjuvant chemotherapy (60.4%), and adjuvant radiotherapy (82.9%). CONCLUSION: In Saudi Arabia, a trend of BC incidence migration towards older patients may be ensuing. However, prediction of an advanced and aggressive presentation requires the enhancement of screening programs and standardized protocols for disease management.
Subject(s)
Breast Neoplasms , Humans , Middle Aged , Female , Breast Neoplasms/epidemiology , Breast Neoplasms/therapy , Saudi Arabia/epidemiology , Mastectomy , Biopsy , FamilyABSTRACT
Background: This study aimed to investigate the expression profile of TFE3 in renal cell carcinoma (RCC) and the clinicopathological features as well as prognosis of TFE3-positive RCC. Methods: Tissue sections from 796 patients with RCC were collected for immunohistochemical staining of TFE3. Molecular TFE3 rearrangement tests were also carried out on the TFE3-positive RCCs using fluorescence in situ hybridization and RNA-sequencing assays. Both clinicopathological features and follow-up information were collected for further analysis. Results: The present study showed that 91 patients with RCC (91/796, 11.4%) were TFE3 positive expression but only 31 (31/91, 34.1%) of the patients were diagnosed with Xp11.2 translocation RCC. Further, it was found that the patients with TFE3-positive RCCs were more likely to develop lymph node and distant metastasis at diagnosis as well as presented a significantly higher WHO/ISUP nuclear grade and AJCC stage as compared with patients with TFE3-negative RCCs (p<0.01). Results of univariate and multivariate analyses showed that TFE3 positive expression was an independent prognostic factor associated with poor progression-free survival. Further, the findings of survival analysis showed that patients with positive TFE3 expression showed a shorter progression-free survival as compared with the patients with negative expression of TFE3 (p<0.001). In addition, results of the survival analysis found that there was no significant difference in progression-free survival between the Xp11.2 translocation RCC and TFE3-positive non-Xp11.2 translocation RCC groups (p=0.9607). Conclusion: This study found that nuclear TFE3 expression is not specific to the Xp11.2 translocation RCC. Moreover, the positive TFE3 expression is associated with tumor progression and poor prognosis in patients with RCC irrespective of the presence of TFE3 translocation.
ABSTRACT
BACKGROUND: Lassa fever is a zoonotic, acute viral illness first identified in Nigeria in 1969. An estimate shows that the "at risk" seronegative population (in Sierra Leone, Guinea, and Nigeria) may be as high as 59 million, with an annual incidence of all illnesses of 3 million, and fatalities up to 67 000, demonstrating the serious impact of the disease on the region and global health. METHODS: Histopathologic evaluation, immunohistochemical assay, and electron microscopic examination were performed on postmortem tissue samples from 12 confirmed Lassa fever cases. RESULTS: Lassa fever virus antigens and viral particles were observed in multiple organ systems and cells, including cells in the mononuclear phagocytic system and other specialized cells where it had not been described previously. CONCLUSIONS: The immunolocalization of Lassa fever virus antigens in fatal cases provides novel insightful information with clinical and pathogenetic implications. The extensive involvement of the mononuclear phagocytic system, including tissue macrophages and endothelial cells, suggests participation of inflammatory mediators from this lineage with the resulting vascular dilatation and increasing permeability. Other findings indicate the pathogenesis of Lassa fever is multifactorial and additional studies are needed.
Subject(s)
Lassa Fever , Virus Diseases , Endothelial Cells , Humans , Incidence , Lassa Fever/epidemiology , Lassa virusABSTRACT
Human adenoviruses can cause infections at any age but most commonly in pediatric population, especially in young children and infants. By the time of 10 years old, most children have had at least one episode of adenovirus infection. Adenoviruses can cause many symptoms similar to common cold, including rhinorrhea, fever, cough, and sore throat. Lower respiratory infections such as bronchitis, bronchiolitis, and pneumonia can be severe and even fatal. Other diseases such as conjunctivitis, gastroenteritis, cystitis, myocarditis, cardiomyopathy, and meningoencephalitis can also be associated with adenovirus infections. A variety of recent advancement of structural and molecular biology methods have revamped the taxonomy of adenoviruses and furthered our understanding of the diversity of related clinical diseases. Because of the wide spectrum and complexity of diseases associated with human adenovirus infections, the scope of this review is limited to basic virology and epidemiology of adenoviruses with a main focus on the clinico-pathologic correlation. Clinical manifestations and pathology of any infectious disease are always related; therefore, it is logical to review clinico-pathologic correlation within the specific disease entity caused by adenoviruses to better understand this common viral infection in pediatric population.
Subject(s)
Adenovirus Infections, Human , Adenoviruses, Human , Respiratory Tract Infections , Adenovirus Infections, Human/diagnosis , Adenovirus Infections, Human/epidemiology , Child , Child, Preschool , Cough , Fever , Humans , Infant , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiologyABSTRACT
INTRODUCTION: We sought to examine whether levels of soluble alpha-synuclein (α-syn), amyloid-beta (Aß42), phosphorylated tau (p-tau), and total tau (t-tau), as measured in cerebrospinal fluid (CSF), are associated with changes in brain volume in Parkinson's disease. METHODS: We assessed the 4-year change in total brain volume (n = 99) and baseline CSF α-syn, Aß42, p-tau, and t-tau of Parkinson Progression Markers Initiative participants. We used linear mixed models to assess the longitudinal effect of baseline CSF biomarkers on total and regional brain volume and thickness as well as linear regression for cross-sectional analyses at baseline and year 2. All models were adjusted for age and gender; brain volume models also adjusted for baseline intracranial volume. Bonferroni correction was applied. RESULTS: The 4-year change in total brain volume was -21.2 mm3 (95% confidence interval, -26.1, -16.3). There were no significant associations between the 4-year change in total brain volume and baseline levels of any CSF biomarker (all p-values > 0.05). On cross-sectional analyses, CSF Aß42 was linearly associated with total brain volume at baseline (R2 = 0.60, p = 0.0004) and at year 2 (R2 = 0.66, p < 0.0001), with CSF Aß42 < 1100 pg/ml, the threshold for brain amyloid pathology, associated with smaller total brain volume at baseline (p = 0.0010) and at year 2 (p = 0.0002). CSF α-syn was linearly associated with total brain volume at baseline (R2 = 0.58, p = 0.0044) but not at year 2 (R2 = 0.58, p = 0.1342). CONCLUSION: Reduction in soluble Aß42 is associated with lower total brain volume in Parkinson's disease.
Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Brain/pathology , Parkinson Disease/cerebrospinal fluid , Parkinson Disease/pathology , Peptide Fragments/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Cross-Sectional Studies , Female , Humans , Linear Models , Longitudinal Studies , Male , Middle Aged , Organ Size , alpha-Synuclein/cerebrospinal fluid , tau Proteins/cerebrospinal fluidABSTRACT
IgG4-related disease (IgG4-RD) is a multisystem fibroinflammatory condition; this can be a challenging diagnosis that requires clinico-pathologic correlation. We report a young woman, presenting with cranial nerve palsy. The work-up revealed pachymeningitis, cerebral venous thrombosis (CVT), and a destructive lesion in the mastoid. We diagnosed IgG4-RD through mastoidectomy. Thus, a biopsy of asymptomatic, infrequently affected organs, like the mastoid, can meet all histopathological criteria. In neuro-meningeal presentations, CVT may be secondary to the local inflammatory environment of pachymeningitis. Since our patient had a deep vein thrombosis one year prior, we discuss a possible higher risk of thrombosis in IgG4-RD patients.
Subject(s)
Immunoglobulin G4-Related Disease/complications , Lateral Sinus Thrombosis/etiology , Mastoiditis/etiology , Meningitis/etiology , Venous Thrombosis/etiology , Abducens Nerve Diseases/etiology , Adrenal Cortex Hormones/therapeutic use , Adult , Dabigatran/therapeutic use , Female , Humans , Immunoglobulin G4-Related Disease/blood , Lung/diagnostic imaging , Magnetic Resonance Imaging , Mastoidectomy , Mastoiditis/diagnostic imaging , Mastoiditis/drug therapy , Mastoiditis/surgery , Meningitis/diagnostic imaging , Meningitis/drug therapy , Neuroimaging , Rituximab/therapeutic use , Thrombophilia/drug therapy , Tomography, X-Ray ComputedABSTRACT
Brain proteins function in their soluble, native conformation and cease to function when transformed into insoluble aggregates, also known as amyloids. Biophysically, the soluble-to-insoluble phase transformation represents a process of polymerization, similar to crystallization, dependent on such extrinsic factors as concentration, pH, and a nucleation surface. The resulting cross-ß conformation of the insoluble amyloid is markedly stable, making it an unlikely source of toxicity. The spread of brain amyloidosis can be fully explained by mechanisms of spontaneous or catalyzed polymerization and phase transformation instead of active replication, which is an enzyme- and energy-requiring process dependent on a specific nucleic acid code for the transfer of biological information with high fidelity. Early neuronal toxicity in Alzheimer's disease may therefore be mediated to a greater extent by a reduction in the pool of soluble, normal-functioning protein than its accumulation in the polymerized state. This alternative loss-of-function hypothesis of pathogenicity can be examined by assessing the clinical and neuroimaging effects of administering non-aggregating peptide analogs to replace soluble amyloid-ß levels above the threshold below which neuronal toxicity may occur. Correcting the depletion of soluble amyloid-ß, however, would only exemplify 'rescue medicine.' Precision medicine will necessitate identifying the pathogenic factors catalyzing the protein aggregation in each affected individual. Only then can we stratify patients for etiology-specific treatments and launch precision medicine for Alzheimer's disease and other neurodegenerative disorders.
Subject(s)
Alzheimer Disease/physiopathology , Amyloid/metabolism , Amyloidosis/metabolism , Brain/pathology , Humans , Neurons/metabolism , Precision MedicineABSTRACT
BACKGROUND: Endoscopic submucosal dissection (ESD) is gaining enormous popularity in the treatment of early gastric cancers (EGCs) in many institutions across the world. However, appropriate selection of candidates for endoscopic resection is crucial to sufficiently mitigate non-e-curative (NEC) resection. This study aims at identifying the various clinico-pathologic factors that independently predict the NEC outcome and depth of submucosal invasion following ESD procedure in patients with EGC. METHODS: Multiple logistic regression analysis was applied to investigate factors that independently predict both non-curability phenomenon and the level of submucosal invasion in patients with early gastric neoplasia. Statistical Packages for the Social Sciences version 23 was used for analysis. RESULTS: A total of 153 patients (162 EGC lesions) underwent en-bloc ESD after which the rate of complete resection and non-e-curative outcome were 95% and 22.2%, correspondingly. Multivariate analysis depicted that tumor location in the upper two third of stomach (odds ratio [OR], 5.46; 95% confidence interval [95% CI], 1.65-18.12; p = 0.006), tumor size > 2 cm (OR, 7.63; 95% CI, 2.29-25.42; p = 0.001), histologically undifferentiated tumor (OR, 15.54; 95% CI, 1.65-146.22; p = 0.001), and tumors with 0-IIa/0-IIc or their mixed variants with predominant 0-IIa/0-IIc (OR, 9.77; 95% CI, 1.23-77.65; p = 0.031) were all independent predictors of NEC resection for early gastric tumors. Additionally, location in the upper two third of the stomach (OR, 8.88; 95% CI, 2.90-27.17; p < 0.001), ulcerated lesions (OR, 3.70; 95% CI, 1.15-11.90; p = 0.028), lesions with > 2 cm (OR, 2.94; 95% CI, 1.08-8.02; p = 0.036) and those with poor differentiation (OR, 6.51; 95% CI, 2.23-18.98; p = 0.001) were found to have significant association with submucosal invasion. CONCLUSIONS: Tumors located in the upper two third of the stomach having a larger size (> 2 cm), poor histo-differentiation and a gross type of 0-IIa/0-IIc or their mixed variants with predominant 0-IIa/0-IIc were significantly associated with a risk of NEC after ESD procedure. Thus, early gastric tumors displaying these features need to be handled carefully during endoscopic resection. Our findings may shed light on the pre-procedural detection of clinicopathologic factors that determine non-e-curability in patients with EGC.
Subject(s)
Early Detection of Cancer/methods , Endoscopic Mucosal Resection/methods , Gastric Mucosa/pathology , Gastroscopy/methods , Precancerous Conditions/pathology , Stomach Neoplasms/pathology , Female , Follow-Up Studies , Gastric Mucosa/surgery , Humans , Male , Middle Aged , Precancerous Conditions/surgery , Prognosis , Retrospective Studies , Risk Factors , Stomach Neoplasms/surgeryABSTRACT
Cancer-associated fibroblasts are essential modifiers of the tumor microenvironment. The collagen-binding integrin α11ß1 has been proposed to be upregulated in a pro-tumorigenic subtype of cancer-associated fibroblasts. Here, we analyzed the expression and clinical relevance of integrin α11ß1 in a large breast cancer series using a novel antibody against the human integrin α11 chain. Several novel monoclonal antibodies against the integrin α11 subunit were tested for use on formalin-fixed paraffin-embedded tissues, and Ab 210F4B6A4 was eventually selected to investigate the immunohistochemical expression in 392 breast cancers using whole sections. mRNA data from METABRIC and co-expression patterns of integrin α11 in relation to αSMA and cytokeratin-14 were also investigated. Integrin α11 was expressed to varying degrees in spindle-shaped cells in the stroma of 99% of invasive breast carcinomas. Integrin α11 co-localized with αSMA in stromal cells, and with αSMA and cytokeratin-14 in breast myoepithelium. High stromal integrin α11 expression (66% of cases) was associated with aggressive breast cancer features such as high histologic grade, increased tumor cell proliferation, ER negativity, HER2 positivity, and triple-negative phenotype, but was not associated with breast cancer specific survival at protein or mRNA levels. In conclusion, high stromal integrin α11 expression was associated with aggressive breast cancer phenotypes.
Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Carcinoma/metabolism , Integrin alpha Chains/biosynthesis , Aged , Antibodies, Monoclonal , Carcinoma/pathology , Female , Humans , Integrin alpha Chains/analysis , Integrins/analysis , Integrins/biosynthesis , Middle Aged , Phenotype , Receptors, Collagen/analysis , Receptors, Collagen/biosynthesisABSTRACT
We present the clinicopathologic conference of a 34-year-old lady with history of facial palsy 14 years ago who developed new deficits of mononeuritis multiplex, maculopapular rash, pancytopenia, splenomegaly, lung involvement and cognitive decline rapidly over three years. Investigations revealed pancytopenia, reversal of albumin globulin ratio, mediastinal adenopathy, ANA positivity, low C3 levels with the CSF being inflammatory and MRI showing extensive hemorrhagic lesions with mass effect. She had a rapidly progressive fatal course over three years with the disease being undiagnosed. This case was presented in the annual meeting of the Indian Academy of Neurology in September 2018.
ABSTRACT
OBJECTIVE: Non-Hodgkin lymphomas (NHL) are a group of neoplastic lymphoproliferative disorders, in which, its clinical spectrum, primary extra nodal variety, histopathology and Immunohistochemistry, remain lacking in Saudi Arabia. We aimed to assess the clinicopathologic patterns of NHL and the utility and diagnostic role of IHC immunophenotyping. RESULTS: Patients > 60 years of age had the highest incidence of NHL; male: female ratio was 1.27:1. The incidence of NHL has shown a steady increase in the Aseer region from 2011 to 2014. Twenty-Five percent of our patients presented with advanced disease (Stage IV). A total of 52% of patients presented with constitutional symptoms, while 43% showed generalized lymphadenopathy. Nearly half of our patients (49%) had primary NHL of extra nodal variety, where the stomach was the most commonly involved organ (13 cases). Diffuse large B cell lymphoma was the most common subtype of NHL in our population (59%). Most patients (82%) were positive for CD20 surface marker, while 60% were positive for CD45.
Subject(s)
Lymphoma, Non-Hodgkin/pathology , Stomach Neoplasms/pathology , Adolescent , Adult , Antigens, CD20/metabolism , Child , Child, Preschool , Female , Humans , Immunohistochemistry , Immunophenotyping , Incidence , Infant , Infant, Newborn , Leukocyte Common Antigens/metabolism , Lymphoma, Non-Hodgkin/epidemiology , Lymphoma, Non-Hodgkin/metabolism , Male , Middle Aged , Neoplasm Staging , Saudi Arabia/epidemiology , Stomach Neoplasms/epidemiology , Stomach Neoplasms/metabolism , Young AdultABSTRACT
Circulating microRNAs have been recognized as promising biomarkers for the detection of lung cancer. The objective of this study was to evaluate miR-10b, miR-1 and, miR-30a in the plasma samples of lung cancer patients to confirm any possible relevance in the early detection of lung cancer. Plasma samples from 47 non-small-cell lung cancer patients and 41 cancer-free subjects were evaluated for selected microRNAs using the real-time PCR method. To evaluate the tobacco smoking effects on microRNAs expression, the studied groups were categorized into two subgroups: never-smokers and smokers. MiR-1/miR-30a expression levels were significantly reduced in lung cancer, while the miR-10b level was significantly elevated. We found that smoking had significant effects on the levels of circulating microRNAs in the smokers of the cancer-free group (a significant up-regulation of miR-10b and significant down-regulation of miR-1/miR-30a), and lung cancer patients (a significant elevation of miR-10b). Receiver operating characteristic curve analysis showed that miR-10b with an area under the curve of 0.861, and miR-1/miR-30a with values of0.905 and 0.889 for the same parameter, could distinguish non-small-cell lung cancer patients from cancer-free subjects. Our findings demonstrated significant differences in the expression of microRNAs in lung cancer and the considerable effects of smoking on microRNAs levels. Area under curve analysis showed that miR-10b with 78% sensitivity/78% specificity, miR-1 with 95% sensitivity/80% specificity and miR-30a with 87% sensitivity/83% specificity,might be good (miR-10b/miR-30a) and excellent (miR-1) markers for lung cancer detection.
ABSTRACT
Parkinson disease has been considered for practical purposes a heterogeneous clinico-pathological entity. The operational definition requires clinical ascertainment of a levodopa-responsive parkinsonism with no "atypical" features, and pathological criteria based on the finding, usually at postmortem, of aggregates of α-synuclein in Lewy bodies and Lewy neurites. The underlying assumption has been that a molecular-biological disorder, targetable for disease modification as a whole, underlies this clinico-pathologic, convergent model of disease. The 2020s will be expected to mark the beginning of the end for this model, especially if therapeutic success in a specific molecular subtype, such as PD-GBA, is not translated to "sporadic PD". The complex and dynamic biological abnormalities of aging, which have informed the evolution of other fields in medicine into divergent, systems-biology models, will also provide the template for the development of disease modifying therapies for neurodegenerative disorders. In the 2020s and 2030s we will no longer ask whether any given molecule may be neuroprotective in early Parkinson disease but, rather, which subtype (which endophenotype) among the Parkinson diseases would be the best mechanistic recipient for such molecule and which would not. The next breakthrough in Parkinson's research will be conceptual: the recognition that discoveries in a subtype of PD will apply only or largely to that subtype and not construed to represent "a piece" that seamlessly inserts into, and helps explains, a unifying "Parkinson's puzzle". Successful neuroprotection for each PD subtype will likely require pharmacotherapeutic combinations ("drug cocktails") to harness synergistic potential benefits when more than the dominant pathogenic mechanism is targeted, as identified from forthcoming population-based unbiased biomarker discovery programs.
Subject(s)
Brain/pathology , Parkinson Disease/therapy , Parkinsonian Disorders/therapy , Disease Management , Humans , Lewy Bodies/pathology , Parkinson Disease/genetics , Parkinson Disease/pathology , Parkinsonian Disorders/genetics , Parkinsonian Disorders/pathology , Systems Biology , alpha-Synuclein/geneticsABSTRACT
Immune mechanisms have been increasingly recognized in the pathogenesis of hippocampal sclerosis (HS), but infiltration of cytotoxic T-cells and its pathological significance in patients with HS has not been explored. We examined 30 cases of surgically resected hippocampi, including 16 International League Against Epilepsy (ILAE) type 1, 9 ILAE type 2, 1 ILAE type 3 HS, and 4 ILAE No-HS, as well as 6 autopsy No-HS hippocampi. The HS hippocampi showed sparse to scattered CD8-positive T-cells, rare CD4-positive T-cells, and a modest increase in CD68-positive microglia/macrophages, which were significantly more numerous than those in the No-HS controls. The infiltration of CD8-positive T-cells was significantly greater in the CA1 subfield than other subfields of type 1 and type 2 HS. The numbers of CD8-positive T-cells positively correlated with those of CD4-positive T-cells; there was a lower ratio of CD4/CD8-positive T-cells. There were positive correlations between these cells and scores of neuronal loss but no significant correlation between the infiltration of these cells and epilepsy disease duration or age of epilepsy onset. These findings suggest that an autoimmune process may be involved in the pathogenesis of HS and infiltration of immune cells, particularly CD8-positive cytotoxic T-cells, may contribute to neuronal loss in HS.
Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Epilepsy/metabolism , Hippocampus/metabolism , Immunity, Cellular/physiology , Neurons/metabolism , Adolescent , Adult , Aged , Child, Preschool , Epilepsy/pathology , Female , Hippocampus/pathology , Humans , Male , Middle Aged , Neurons/pathology , Retrospective Studies , Sclerosis/metabolism , Sclerosis/pathology , Young AdultABSTRACT
AIM: The current study aimed to explore the distribution patterns of 21-gene recurrence score (RS) assay in Chinese early breast cancer patients. METHODS: Nine hundred and eighty consecutive estrogen receptor(ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer patients treated at Ruijin Hospital, Shanghai Jiaotong University, School of Medicine from 2009 to 2016 were retrospectively recruited. Reverse transcriptase-polymerase chain reaction (RT-PCR) assay of 21 genes were conducted in paraffin-embedded tumor tissue to calculate the RS. Co-relations of RS and clinico-pathologic factors were evaluated. Concordances of RT-PCR and immunohistochemistry (IHC) tests were measured. Logistic regression were applied to determine independent variables associated with RS. RESULTS: The median RS of 980 patients was 23(0~90), and the proportions of patients categorized as having a low, intermediate, or high risk were 26.1%, 49.3% and 24.6%. The distribution of RS varied significantly according to different tumor grade, T stage, progesterone receptor(PR) status, Ki67 index and molecular subtypes (p<0.05). Grade, PR status and Ki67 index were identified as independent variables associated with RS. The concordance rates between RT-PCR and IHC test were 98.8% and 88.3% for ER and PR status, and there were weak to moderate correlation between IHC and RT-PCR tests for ER, PR expression and Ki67 index. CONCLUSIONS: RS correlated significantly with grade, T stage, PR status, Ki67 index and molecular subtypes in Chinese early breast cancer patients. Grade, PR status and Ki67 index could independently predict RS. ER, PR status and Ki67 index between RT-PCR and IHC test had remarkable concordance.
Subject(s)
Asian People/genetics , Biomarkers, Tumor/genetics , Breast Neoplasms/diagnosis , Carcinoma, Ductal, Breast/diagnosis , Neoplasm Recurrence, Local/diagnosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Adult , Aged , Aged, 80 and over , Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Female , Follow-Up Studies , Gene Expression Profiling , Humans , Middle Aged , Neoplasm Invasiveness , Neoplasm Recurrence, Local/genetics , Prognosis , Receptors, Progesterone/metabolism , Retrospective Studies , Survival RateABSTRACT
La calidad diagnóstica es el resultado de integrar el conocimiento médico y reconocimiento de los errores clínicos, se alcanza únicamente con la identificación de las causas de muerte; es la correlación clínico patológica la herramienta principal para dicha acción. El objetivo general de la investigación fue determinar la discrepancia clínico-patológica y su relación con otras variables en las autopsias realizadas en la institución. Se revisaron 159 protocolos de autopsia del período comprendido entre enero 2012 y junio 2016, elaborados por el Servicio de Patología del Hospital Escuela Universitario de Tegucigalpa, Honduras. Se excluyeron 36 por no cumplir los criterios de inclusión. Se utilizaron la CIE-10 y la clasificación de Goldman et al. para clasificar las patologías y establecer las discrepancias diagnósticas, respectivamente. El sexo predominante fue el femenino (2,96:1), la edad media fue de 38 años; prevalecieron los diagnósticos de embarazo/parto/puerperio y enfermedades infecciosas y parasitarias. Concluimos que en 46% de los casos existe discrepancia diagnóstica y la glomerulonefritis fue la principal causa de error, seguida de bronconeumonía. Se recomienda estandarizar el protocolo de autopsias y promover sesiones clínico-patológicas periódicas e integrales.
Diagnostic quality is the result of the integration of medical knowledge and recognition of clinical error, achieved only by identifying the cause of death; clinical pathological correlation is the primary tool for this action. The overall objective of this research was to determine clinical pathological discrepancy and its relationship with other variables within the autopsies performed at the institution. 159 autopsy protocols, elaborated by the Department of Pathology of Hospital Escuela Universitario in Tegucigalpa, Honduras, from January 2012 to June 2016, were reviewed. 36 were excluded for not meeting the inclusion criteria. ICD-10 and Goldman et al. modified by Battle criteria were used to classify diseases and establish diagnostic discrepancies, respectively. The majority of patients were female (2.96:1), the mean age was 38 years old; diagnoses of pregnancy/birth/puerperium and infectious and parasitic diseases prevailed. We conclude that diagnostic discrepancies exist in 46% of all cases and glomerulonephritis was the leading cause of error, followed by bronchopneumonia. It is recommended that autopsy protocols be standardized, and integrative clinical pathological sessions are promoted and integral.
Subject(s)
Autopsy/statistics & numerical data , Clinical Diagnosis , Lung Diseases/mortalityABSTRACT
In Response to: Giorelli M, Losignore NA, Bagnoli J, et al. The progression of posterior cortical atrophy to corticobasal syndrome: Lumping or splitting neurodegenerative diseases? Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D81G0JCQ.
ABSTRACT
OBJECTIVE: Cystic ameloblastoma represent 10-15% of all intra osseous ameloblastomas and appear to be less aggressive than the solid ameloblastomas. The aim of this study was to examine the clinico-pathologic characteristics of cystic ameloblastomas seen at a tertiary health care centre. MATERIALS: All cases diagnosed as cystic ameloblastoma in the Oral Pathology Department of University College Hospital, Ibadan over a 10 year period were investigated for age, gender, location of lesion, treatment, and follow-up. The cases were classified as luminal, intraluminal or mural, based on Ackermann classification. The data was entered into the statistical package for the social sciences version 18 (SPSS 18) and results expressed as percentages. RESULTS: Fifteen cystic ameloblastomas, representing 14.3% of a total of 105 ameloblastoma cases were seen. The mean age was 28.9(±14.5) years with 73.4% occurring in the second and third decades. The male:female ratio was 2:3. Fourteen (93.3%) of the lesions were in the mandible while only one (6.7%) was in the maxilla. The mural variant was the most common histological variant with 6(40%) cases while the luminal and intra-luminal had 4(26.7%) and 5(33.3%) respectively. The multilocular radiologic appearance was more common than the unilocular in this study (ratio 8:4). Cystic ameloblastoma with multilocular appearance occurred in a higher age group (mean age 31yrs) when compared with the unilocular type which had a mean age of 16.3years. CONCLUSION: This study shows similar findings with previous studies but shows a higher multilocular radiological appearance as compared to unilocular variant and no case of recurrence.
ABSTRACT
Objective:To study the clinico-pathologic characteristics, molecular phenotypes, and prognosis of young breast can-cer patients. Methods:Data from 133 low-age (age≤30 years) young breast cancer patients and 117 young (31 years≤age≤35 years) breast cancer patients who underwent surgery between January 2002 and December 2009 were reviewed. Cases of the middle and old-age elderly (age>35 years) breast cancer patients during the corresponding period were randomly selected as matched controls. The clinico-pathologic characteristics, molecular phenotypes, and prognosis were retrospectively analyzed. Results:The low-age young and young breast cancer patients significantly differed from the elderly patients in terms of tumor size, lymph node metastasis, histological grading, molecular phenotype, and relapse (P<0.05). The low-age young patients are more vulnerable to have triple-negative breast can-cer, recurrence, and distant metastasis (P<0.001). Moreover, the low-age young patients have lower overall survival and disease-free survival than the other groups (P<0.05). Conclusion:Young breast cancer patients have poor prognosis compared with the elderly. Ear-ly screening and prompt treatment are necessary for young breast cancer patients.
ABSTRACT
We report early experience of a case-mix series of robotic-assisted (RA) gynecologic/oncologic surgery in an Arabian population from a tertiary care facility, and discuss the emergence/growth of robotic surgery in the Arab world (Middle East). From December 2005 to December 2010, 60 consecutive patients [benign with complex pathology (BN, n = 34) and 26 cases with various malignancies; i.e., endometrial cancer (EC, n = 13), ovarian cancer (OC, n = 4), cervical cancer (CC, n = 1), and other cancers (OTH, n = 8), underwent RA procedures for the diagnosis/treatment/management of gynecologic/oncologic diseases at a single institution using the da Vinci(®) Surgical System. Data were analyzed for demographics, clinico-pathologic and peri/post-operative factors using intent-to-treat analysis. Despite continuous growth in the number of cases performed each year, the establishment of the robotic surgery program at our institution has been rather challenging due to patient acceptance, public awareness, and administrative resistance. The mean age of the case-mix was 43 ± 15 years (distribution: BN 39 ± 14, EC 61 ± 6, OC 36 ± 15, CC 50, OTH 41 ± 12 years). The body mass index for the case-mix was 30.3 ± 6.9 kg/m(2) (distribution: BN 29.7 ± 6.2, EC 34.0 ± 3.6, OC 20.0 ± 1.7, CC 48, OTH 30.2 ± 6.2 kg/m(2)). The histology of most EC cases was endometrioid adenocarcinoma. The mean operative time was case-mix 95 ± 43, BN 77 ± 26, EC 156 ± 30, OC 80 ± 35, CC 150, OTH 79 ± 23 min. Mean blood loss was case-mix 126, BN 129, EC 177, OC 67, CC 50, OTH 71 min. Two cases (3.3%) were converted to laparotomy (one each in EC and BN groups). Mean hospital length of stay was 2 days. Four cases (6.7%) experienced complications. Only 4/26 (15.4%) of cancer cases required adjuvant therapy. The data suggest that RA gynecologic/oncologic procedures are feasible and satisfactory to our Arabian patient population and comparable to the existing literature for Caucasian counterparts. We believe this report is the first (and perhaps largest) case-mix series on the early experience of RA surgery for gynecologic/oncologic cases from the Middle East.